-
Jul.112018NEWS
HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch of Immunovant
HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch..
-
Jun.252018NEWS
HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World Health Organization(WHO)
HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World He..
-
May.292018NEWS
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036(a new drug for dry eye syndrome) in the U.S.
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036..
-
May.292018NEWS
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036(a new drug for dry eye syndrome) in the U.S.
HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036..
-
May.242018NEWS
IM156, a new drug with original technology of HanAll Biopharma, is to be Introduced at the American Society of Clinical Oncology
IM156, a new drug with original technology of HanAll Biopharma, is to be Introduced at the American ..
-
Apr.232018NEWS
Seung-kook Park, CEO of HanAll Biopharma Awarded of the President’s Citation on the Science Day
Seung-kook Park, CEO of HanAll Biopharma Awarded of the President’s Citation on the Science Day